Next-Generation Bispecific Nanobody Targeting CD3 Complex and GPC3 for Liver Cancer Therapy
VHH-P401 is an innovative bispecific humanized nanobody designed to target the CD3 Complex (T Cell Receptor Complex) and glypican 3 (GPC3). Developed by advanced protein engineering, VHH-P401 is currently in the biological testing phase and shows promising therapeutic potential for the treatment of liver cancer. By simultaneously binding to CD3 Complex (T Cell Receptor Complex) on immune cells and GPC3 on tumor cells, this agent aims to redirect T cell activity to tumor sites, opening new avenues for immunotherapeutic intervention in liver cancer.
| Candidate | VHH-P401 |
| Target | CD3 Complex (T Cell Receptor Complex) glypican 3 (GPC3) |
| Modality | humanized bispecific VHH |
| Indication | Liver Cancer |
Licensing Opportunity
VHH-P401 is available for external licensing opportunities. Potential partners are invited to collaborate in the development and commercialization of this innovative bispecific nanobody for liver cancer therapy.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P401 |
Modality
VHH-P401 is a bispecific humanized monoclonal IgG antibody with a nanobody-derived variable domain architecture. It consists of two heterologous heavy chains: one carries a variable heavy chain targeting GPC3 linked to a knob Fc domain, while the other comprises a single-chain fragment targeting CD3 fused to a hole Fc domain. Expressed in HEK 293 cells, this modular structure not only ensures high specificity but also leverages the small size and high stability characteristic of nanobodies. Such properties enhance tumor penetration and enable binding to otherwise hard-to-access epitopes, offering distinct advantages in targeting liver cancer cells within the challenging microenvironment of solid tumors.
Target
CD3 Complex and GPC3 are the dual targets of VHH-P401. The CD3 Complex is an essential component of the T cell receptor, mediating T cell activation and immune signaling. It is predominantly expressed on mature T lymphocytes and plays a pivotal role in antigen recognition. GPC3 is a membrane-bound heparan sulfate proteoglycan highly expressed on liver cancer cells but limited in normal tissues. Targeting GPC3 allows for selective tumor cell recognition. The combinatorial targeting of CD3 Complex and GPC3 by VHH-P401 effectively bridges immune effector cells to tumor cells, enhancing tumor-specific cytotoxicity. This strategy maximizes the anti-tumor potential while minimizing off-tumor effects, positioning VHH-P401 as a highly valuable asset in liver cancer immunotherapy development.
Mechanism of Action
VHH-P401 operates by binding to GPC3 on tumor cell surfaces and CD3 Complex on T cells. Its bispecific configuration enables it to bring T cells directly in contact with GPC3-expressing cancer cells. This facilitates targeted immune synapse formation, T cell activation, and subsequent tumor cell killing. As a signal transduction modulator, it effectively harnesses the body’s immune system to induce a cytotoxic response selectively within the tumor microenvironment. The nanobody-based bispecific approach also offers an adaptable platform for future derivations, such as antibody drug conjugates (ADCs) or further dual-targeted biologics, broadening the therapeutic applicability for solid tumors like liver cancer.
Liver Cancer
Liver cancer is a significant global health challenge, with high morbidity and mortality rates. Hepatocellular carcinoma represents the most common form, and its incidence continues to rise, largely associated with risk factors such as chronic hepatitis infection, alcohol-related liver disease, and metabolic disorders. Standard treatments include surgical resection, local ablative therapies, chemotherapy, and targeted agents. However, many patients present at advanced stages, limiting curative options. Despite emergence of immunotherapy and targeted approaches, liver cancer remains difficult to treat due to its immune-evasive tumor microenvironment and underlying liver dysfunction in many patients. There is a pressing need for novel, effective strategies that can harness the immune system for specific tumor targeting. VHH-P401, by engaging both CD3 Complex and GPC3, offers a promising immunotherapeutic avenue, potentially addressing unmet medical needs and improving patient outcomes in this population.